/PRNewswire/ According to 17PR reports: the first English case studies collection in China s brand public relations and marketing industry, titled Public.
/PRNewswire/ Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes.
A fireside chat between Purdue University President Mitch Daniels and David Ricks, chair and CEO of Eli Lilly and Company, will be the highlight of the seventh annual Lilly Day at Purdue on Wednesday (Aug. 31).
SAN FRANCISCO, INDIANAPOLIS and SUZHOU, China, June 21, 2022 /PRNewswire/ Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, autoimmune, metabolic, ophthalmology and other major diseases, and Eli Lilly and Company ("Lilly", NYSE: LLY) today announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has approved the supplemental New Drug Application (sNDA) for TYVYT (sintilimab injection) in combination with cisplatin plus paclitaxel or cisplatin plus 5-fluorouracil chemotherapy for the first-line treatment of unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC). This is the fifth NMPA-approved indication of TYVYT. In China, TYVYT was approved for: the treatment of relapsed or refractory classical Hodgkin's lymphoma in Dece